(NASDAQ: IDYA) Ideaya Biosciences's forecast annual revenue growth rate of -1.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Ideaya Biosciences's revenue in 2026 is $218,710,000.On average, 21 Wall Street analysts forecast IDYA's revenue for 2026 to be $3,565,600,752, with the lowest IDYA revenue forecast at $0, and the highest IDYA revenue forecast at $8,514,799,314. On average, 18 Wall Street analysts forecast IDYA's revenue for 2027 to be $10,378,739,851, with the lowest IDYA revenue forecast at $3,958,656,337, and the highest IDYA revenue forecast at $16,680,274,429.
In 2028, IDYA is forecast to generate $18,872,990,683 in revenue, with the lowest revenue forecast at $9,036,063,378 and the highest revenue forecast at $30,068,400,985.